Gold nanoparticles as novel agents for cancer therapy

S Jain, DG Hirst, JM O'Sullivan - The British journal of radiology, 2012 - academic.oup.com
Gold nanoparticles are emerging as promising agents for cancer therapy and are being
investigated as drug carriers, photothermal agents, contrast agents and radiosensitisers …

18F-FDG PET/CT Imaging In Oncology

A Almuhaideb, N Papathanasiou… - Annals of Saudi …, 2011 - annsaudimed.net
Accurate diagnosis and staging are essential for the optimal management of cancer
patients. Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose …

Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice …

GA Silvestri, AV Gonzalez, MA Jantz, ML Margolis… - Chest, 2013 - Elsevier
Background Correctly staging lung cancer is important because the treatment options and
prognosis differ significantly by stage. Several noninvasive imaging studies and invasive …

Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the …

J Okami, Y Shintani, M Okumura, H Ito… - Journal of Thoracic …, 2019 - Elsevier
Abstract Introduction The Japanese Joint Committee of Lung Cancer Registry performed the
fourth nationwide registry study of surgical cases. Demographics, safety and quality …

Role of FDG PET/CT in the eighth edition of TNM staging of non–small cell lung cancer

A Kandathil, FU Kay, YM Butt, JW Wachsmann… - Radiographics, 2018 - pubs.rsna.org
Lung cancer is the leading cause of cancer-related mortality in the United States, and
accurate staging plays a vital role in determining prognosis and treatment. The recently …

[PDF][PDF] American Society of Clinical Oncology treatment of unresectable non–small-cell lung cancer guideline: Update 2003

DG Pfister, DH Johnson, CG Azzoli… - Journal of Clinical …, 2004 - spitalmures.ro
The American Society of Clinical Oncology (ASCO) previously published evidencebased
guidelines for the treatment of unresectable non–small-cell lung cancer (NSCLC)[1]. ASCO …

Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non–small-cell lung cancer: a meta-analysis

MK Gould, WG Kuschner, CE Rydzak… - Annals of internal …, 2003 - acpjournals.org
Purpose: To compare the diagnostic accuracy of computed tomography (CT) and positron
emission tomography (PET) with 18-fluorodeoxyglucose (FDG) for mediastinal staging in …

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre …

H Van Tinteren, OS Hoekstra, EF Smit… - The Lancet, 2002 - thelancet.com
Background Up to 50% of curative surgery for suspected non-small-cell lung cancer is
unsuccessful. Accuracy of positron emission tomography (PET) with 18-fluorodeoxyglucose …

Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines

GA Silvestri, MK Gould, ML Margolis, LT Tanoue… - Chest, 2007 - Elsevier
Background Correctly staging lung cancer is important because the treatment options and
the prognosis differ significantly by stage. Several noninvasive imaging studies including …

Noninvasive staging of non-small cell lung cancer: a review of the current evidence

EM Toloza, L Harpole, DC McCrory - Chest, 2003 - Elsevier
Study objectives To determine the test performance characteristics of CT scanning, positron
emission tomography (PET) scanning, MRI, and endoscopic ultrasound (EUS) for staging …